"It is the goal of the Ministry of Public Health to achieve diagnosis of 80 percent of the at-risk population, to treat at least 80 percent of those cases, and to reach hypertension control in 80 percent of them," explained Yagen Pomares, director of Primary Health Care for the ministry.

In Cuba, the prevalence of hypertension reaches 37.3 percent of the total population; the estimated number of hypertensive individuals is 3,152,161, and in the adult population aged 30 to 79, it rises to 40 percent—meaning an estimated 3.1 million adults with hypertension, Pomares specified.

Currently, there are 2.2 million citizens diagnosed as hypertensive in the country, but another 900,000 are not.

Approximately two million are undergoing treatment, but 200,000 lack it due to institutional and personal gaps. Among those under treatment, slightly more than one million have their hypertension under control, while close to one million have not yet achieved it, Pomares stated, as cited by Granma newspaper.

Pomares highlighted that Cuba, at the primary care level, has 451 polyclinics, 10,541 basic health teams, and 22,774 family physicians in communities.

Likewise, the island nation has several thousand specialized physicians, including internists, cardiologists, nephrologists, endocrinologists, neurologists, and cardiovascular surgeons.

The country also has the Hipermax BF automatic blood pressure measurement device for adults, accredited on two international lists of automatic sphygmomanometers.

Added to this, Pomares noted, is the development of new antihypertensive drugs, such as the innovation project Lisinopril 20 mg and Lisinopril/Hydrochlorothiazide 20/25 for the treatment of hypertension, led by entities within Biocubafarma.